NASDAQ:EYPT EyePoint Pharmaceuticals - EYPT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.52 -0.07 (-1.53%) (As of 02/7/2023 10:13 AM ET) Add Compare Share Share Today's Range$4.52▼$4.7050-Day Range$2.37▼$5.0452-Week Range$2.19▼$14.41Volume10,558 shsAverage Volume330,118 shsMarket Capitalization$154.04 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media EyePoint Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside622.7% Upside$32.67 Price TargetShort InterestBearish8.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.15) to ($2.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 starsMedical Sector729th out of 1,027 stocksAnalytical Instruments Industry20th out of 27 stocks 3.5 Analyst's Opinion Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.67, EyePoint Pharmaceuticals has a forecasted upside of 622.7% from its current price of $4.52.Amount of Analyst CoverageEyePoint Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.02% of the float of EyePoint Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently increased by 13.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEyePoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyePoint Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYPT. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for EyePoint Pharmaceuticals this week, compared to 1 article on an average week.Search Interest5 people have searched for EYPT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows6 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EyePoint Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.88% of the stock of EyePoint Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.27% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($2.15) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EyePoint Pharmaceuticals is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EyePoint Pharmaceuticals is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyePoint Pharmaceuticals has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About EyePoint Pharmaceuticals (NASDAQ:EYPT) StockEyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.Read More Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Stock News HeadlinesFebruary 1, 2023 | wsj.comEyePoint Shareholder NoticeJanuary 24, 2023 | wsj.comEyePoint Shareholder Action ReminderFebruary 7, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.January 23, 2023 | markets.businessinsider.comEyePoint To Build 40K Sq. Ft. Facility To Make EYP-1901, YUTIQJanuary 23, 2023 | finance.yahoo.comEyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQJanuary 11, 2023 | finance.yahoo.com2 “Strong Buy” Penny Stocks With Over 400% Upside on the HorizonJanuary 5, 2023 | finance.yahoo.comEyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical TimelinesJanuary 4, 2023 | msn.comEyePoint Pharmaceuticals promotes Jay S. Duker to PresidentFebruary 7, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.January 4, 2023 | finance.yahoo.comEyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating OfficerDecember 20, 2022 | finanznachrichten.deEyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 3, 2022 | wsj.comBragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the FirmDecember 1, 2022 | finance.yahoo.comInvestors in EyePoint Pharmaceuticals (NASDAQ:EYPT) have unfortunately lost 79% over the last yearNovember 2, 2022 | msn.comEyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue EstimatesNovember 2, 2022 | finance.yahoo.comEyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate DevelopmentsOctober 26, 2022 | finance.yahoo.comEyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022October 19, 2022 | marketwatch.comBragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the FirmOctober 11, 2022 | seekingalpha.comEYPT EyePoint Pharmaceuticals, Inc.October 7, 2022 | finance.yahoo.comStrength Seen in Provention Bio, Inc. (PRVB): Can Its 25.7% Jump Turn into More Strength?October 4, 2022 | marketwatch.comEyePoint Investor AlertSeptember 30, 2022 | fool.comEyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT)September 29, 2022 | finance.yahoo.comEyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic RetinopathySeptember 1, 2022 | apnews.comEyePoint Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law FirmAugust 31, 2022 | benzinga.comINVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAugust 31, 2022 | benzinga.comEyePoint Pharmaceuticals Shareholder News: Johnson Fistel Encourages EYPT Shareholders with Losses to Contact the Firm Regarding InvestigationAugust 30, 2022 | apnews.comINVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAugust 3, 2022 | seekingalpha.comEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Company Calendar Last Earnings11/03/2021Today2/07/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYPT CUSIPN/A CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees122Year Founded1987Price Target and Rating Average Stock Price Forecast$32.67 High Stock Price Forecast$52.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+408.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,420,000.00 Net Margins-186.02% Pretax Margin-186.02% Return on Equity-48.00% Return on Assets-31.89% Debt Debt-to-Equity Ratio0.21 Current Ratio5.61 Quick Ratio5.50 Sales & Book Value Annual Sales$35.31 million Price / Sales4.36 Cash FlowN/A Price / Cash FlowN/A Book Value$5.44 per share Price / Book0.83Miscellaneous Outstanding Shares34,080,000Free Float30,034,000Market Cap$154.04 million OptionableOptionable Beta0.99 Social Links Key ExecutivesNancy Sue LurkerChief Executive Officer & DirectorJay S. DukerPresident & Chief Operating OfficerGeorge O. ElstonCFO & Head-Corporate DevelopmentDario A. PaggiarinoChief Medical Officer & Senior Vice PresidentSaid SaimChief Technology OfficerKey CompetitorsStandard BioToolsNASDAQ:LABBerkeley LightsNASDAQ:BLISingular Genomics SystemsNASDAQ:OMICNautilus BiotechnologyNASDAQ:NAUTRapid Micro BiosystemsNASDAQ:RPIDView All CompetitorsInsiders & InstitutionsEssex Investment Management Co. LLCSold 140,164 shares on 2/3/2023Ownership: 0.592%Legato Capital Management LLCBought 76,130 shares on 2/1/2023Ownership: 0.223%Bank of New York Mellon CorpBought 7,388 shares on 12/8/2022Ownership: 0.227%Jane Street Group LLCBought 20,720 shares on 11/16/2022Ownership: 0.061%BNP Paribas Arbitrage SNCBought 9,790 shares on 11/16/2022Ownership: 0.029%View All Institutional Transactions EYPT Stock - Frequently Asked Questions Should I buy or sell EyePoint Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares. View EYPT analyst ratings or view top-rated stocks. What is EyePoint Pharmaceuticals' stock price forecast for 2023? 4 analysts have issued 1 year price targets for EyePoint Pharmaceuticals' shares. Their EYPT share price forecasts range from $21.00 to $52.00. On average, they expect the company's stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 611.7% from the stock's current price. View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts. How have EYPT shares performed in 2023? EyePoint Pharmaceuticals' stock was trading at $3.50 at the start of the year. Since then, EYPT stock has increased by 31.1% and is now trading at $4.59. View the best growth stocks for 2023 here. When is EyePoint Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our EYPT earnings forecast. How were EyePoint Pharmaceuticals' earnings last quarter? EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.11. The company had revenue of $9.06 million for the quarter, compared to analysts' expectations of $9.60 million. EyePoint Pharmaceuticals had a negative net margin of 186.02% and a negative trailing twelve-month return on equity of 48.00%. During the same quarter in the prior year, the business earned ($0.30) earnings per share. When did EyePoint Pharmaceuticals' stock split? EyePoint Pharmaceuticals's stock reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of EyePoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX). What is EyePoint Pharmaceuticals' stock symbol? EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT." Who are EyePoint Pharmaceuticals' major shareholders? EyePoint Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.59%), Legato Capital Management LLC (0.22%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include George Elston and Nancy Lurker. View institutional ownership trends. How do I buy shares of EyePoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is EyePoint Pharmaceuticals' stock price today? One share of EYPT stock can currently be purchased for approximately $4.59. How much money does EyePoint Pharmaceuticals make? EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $156.43 million and generates $35.31 million in revenue each year. The company earns $-58,420,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. How many employees does EyePoint Pharmaceuticals have? The company employs 122 workers across the globe. How can I contact EyePoint Pharmaceuticals? EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050. This page (NASDAQ:EYPT) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.